• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Therapeutic Drug Monitoring of Anti-infective Drugs: Implementation Strategies for 3 Different Scenarios.治疗药物监测抗传染性药物:3 种不同情况的实施策略。
Ther Drug Monit. 2022 Feb 1;44(1):3-10. doi: 10.1097/FTD.0000000000000936.
2
Therapeutic drug monitoring of anti-infective agents in critically ill patients.危重症患者抗感染药物的治疗药物监测
Expert Rev Clin Pharmacol. 2016 Jul;9(7):961-79. doi: 10.1586/17512433.2016.1172209. Epub 2016 Apr 15.
3
Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients.专家临床药理学建议可能使新兴候选药物的抗菌药物治疗药物监测(TDM)计划在为危重症患者制定治疗方案方面更具临床实用性。
Crit Care. 2022 Jun 14;26(1):178. doi: 10.1186/s13054-022-04050-9.
4
Therapeutic Drug Monitoring of Antibiotics in Critically Ill Patients: Current Practice and Future Perspectives With a Focus on Clinical Outcome.危重症患者抗生素的治疗药物监测:以临床转归为重点的当前实践和未来展望。
Ther Drug Monit. 2022 Feb 1;44(1):11-18. doi: 10.1097/FTD.0000000000000942.
5
[Therapeutic monitoring: analytic, pharmacokinetic and clinical aspects].[治疗监测:分析、药代动力学及临床方面]
Acta Clin Belg. 1999;53 Suppl 1:2-12.
6
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper.危重症成人患者的抗菌治疗药物监测:立场文件。
Intensive Care Med. 2020 Jun;46(6):1127-1153. doi: 10.1007/s00134-020-06050-1. Epub 2020 May 7.
7
Barriers and Facilitators in the Clinical Implementation of Beta-Lactam Therapeutic Drug Monitoring in Critically Ill Patients: A Critical Review.β-内酰胺类治疗药物监测在危重症患者临床应用中的障碍和促进因素:批判性评价。
Ther Drug Monit. 2022 Feb 1;44(1):112-120. doi: 10.1097/FTD.0000000000000937.
8
Therapeutic drug monitoring of commonly used anti-infective agents: A nationwide cross-sectional survey of Australian hospital practices.常用抗感染药物的治疗药物监测:澳大利亚医院实践的全国性横断面调查。
Int J Antimicrob Agents. 2020 Dec;56(6):106180. doi: 10.1016/j.ijantimicag.2020.106180. Epub 2020 Sep 25.
9
Salivary Therapeutic Drug Monitoring of Antimicrobial Therapy: Feasible or Futile?唾液治疗药物监测在抗菌治疗中的应用:可行还是徒劳?
Clin Pharmacokinet. 2024 Mar;63(3):269-278. doi: 10.1007/s40262-024-01346-7. Epub 2024 Feb 1.
10
Therapeutic Drug Monitoring of Antibiotics in Critically Ill Children: An Observational Study in a Pediatric Intensive Care Unit.抗生素在危重症患儿中的治疗药物监测:儿科重症监护病房的观察性研究。
Ther Drug Monit. 2022 Apr 1;44(2):319-327. doi: 10.1097/FTD.0000000000000918.

引用本文的文献

1
State of the art of real-life concentration monitoring of rifampicin and its implementation contextualized in resource-limited settings: the Tanzanian case.利福平实际浓度监测的技术现状及其在资源有限环境中的实施情况:以坦桑尼亚为例
JAC Antimicrob Resist. 2024 Nov 14;6(6):dlae182. doi: 10.1093/jacamr/dlae182. eCollection 2024 Dec.
2
Salivary Therapeutic Drug Monitoring of Antimicrobial Therapy: Feasible or Futile?唾液治疗药物监测在抗菌治疗中的应用:可行还是徒劳?
Clin Pharmacokinet. 2024 Mar;63(3):269-278. doi: 10.1007/s40262-024-01346-7. Epub 2024 Feb 1.
3
Rifampin urinary excretion to predict serum targets in children with tuberculosis: a prospective diagnostic accuracy study.利福平尿排泄预测结核病儿童的血清靶标:一项前瞻性诊断准确性研究。
Arch Dis Child. 2023 Aug;108(8):616-621. doi: 10.1136/archdischild-2022-325250. Epub 2023 Apr 25.
4
Alternative Methods for Therapeutic Drug Monitoring and Dose Adjustment of Tuberculosis Treatment in Clinical Settings: A Systematic Review.临床环境中治疗结核病的治疗药物监测和剂量调整的替代方法:系统评价。
Clin Pharmacokinet. 2023 Mar;62(3):375-398. doi: 10.1007/s40262-023-01220-y. Epub 2023 Mar 4.
5
Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis.全球儿童和青少年抗结核药物药代动力学的估计和决定因素:系统评价和个体患者数据荟萃分析。
Eur Respir J. 2023 Mar 9;61(3). doi: 10.1183/13993003.01596-2022. Print 2023 Mar.
6
Clinical standards for the dosing and management of TB drugs.结核病药物剂量和管理的临床标准。
Int J Tuberc Lung Dis. 2022 Jun 1;26(6):483-499. doi: 10.5588/ijtld.22.0188.

治疗药物监测抗传染性药物:3 种不同情况的实施策略。

Therapeutic Drug Monitoring of Anti-infective Drugs: Implementation Strategies for 3 Different Scenarios.

机构信息

Faculty of Medicine and Health, School of Pharmacy, University of Sydney.

Westmead Hospital.

出版信息

Ther Drug Monit. 2022 Feb 1;44(1):3-10. doi: 10.1097/FTD.0000000000000936.

DOI:10.1097/FTD.0000000000000936
PMID:34686647
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8755585/
Abstract

BACKGROUND

Therapeutic drug monitoring (TDM) supports personalized treatment. For successful implementation, TDM must have a turnaround time suited to the clinical needs of patients and their health care settings. Here, the authors share their views of how a TDM strategy can be tailored to specific settings and patient groups.

METHODS

The authors selected distinct scenarios for TDM: high-risk, complex, and/or critically ill patient population; outpatients; and settings with limited laboratory resources. In addition to the TDM scenario approach, they explored potential issues with the legal framework governing dose escalation.

RESULTS

The most important issues identified in the different scenarios are that critically ill patients require rapid turnaround time, outpatients require an easy sampling procedure for the sample matrix and sample collection times, settings with limited laboratory resources necessitate setting-specific analytic techniques, and all scenarios warrant a legal framework to capture the use of escalated dosages, ideally with the use of trackable dosing software.

CONCLUSIONS

To benefit patients, TDM strategies need to be tailored to the intended population. Strategies can be adapted for rapid turnaround time for critically ill patients, convenient sampling for outpatients, and feasibility for those in settings with limited laboratory resources.

摘要

背景

治疗药物监测(TDM)支持个性化治疗。为了成功实施,TDM 的检测周转时间必须符合患者及其医疗保健环境的临床需求。在这里,作者分享了他们如何根据特定环境和患者群体调整 TDM 策略的观点。

方法

作者为 TDM 选择了不同的场景:高危、复杂和/或重症患者人群;门诊患者;以及实验室资源有限的环境。除了 TDM 场景方法外,他们还探讨了管理剂量递增的法律框架中潜在的问题。

结果

在不同场景中确定的最重要问题是,重症患者需要快速的检测周转时间,门诊患者需要针对样本基质和样本采集时间的简单采样程序,实验室资源有限的环境需要特定于环境的分析技术,所有场景都需要一个法律框架来捕捉递增剂量的使用,理想情况下使用可追踪的给药软件。

结论

为了使患者受益,TDM 策略需要针对目标人群进行调整。可以为重症患者制定快速检测周转时间策略,为门诊患者制定方便采样策略,为实验室资源有限的环境制定可行性策略。